Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 11, 2020 at 08:09 am
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 235.449 million compared to TWD 256.578 million a year ago. Operating income was TWD 10.125 million compared to TWD 19.463 million a year ago. Net income was TWD 8.222 million compared to TWD 16.410 million a year ago. Basic earnings per share was TWD 0.14 compared to TWD 0.29 a year ago. For the nine months, sales was TWD 737.868 million compared to TWD 756.258 million a year ago. Operating income was TWD 58.940 million compared to TWD 60.079 million a year ago. Net income was TWD 50.419 million compared to TWD 51.057 million a year ago. Basic earnings per share was TWD 0.88 compared to TWD 0.9 a year ago. Diluted earnings per share was TWD 0.88 compared to TWD 0.89 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.